Ferring Pharmaceuticals announced it was extending the recall of Stimate (desmopressin) to the consumer/user level. Stimate is manufactured by Ferring Pharmaceuticals Inc. and is distributed and sold in the United States by CSL Behring. This marks an expansion of Ferring’s initial July 2020 plans to conduct a narrower pharmacy-level recall.
Under a consumer-level recall, people who have received the affected lots are requested to return the product. Patients who have any lots of Stimate identified in the recall should contact CSL Behring’s patient resource center at: (800) 676-4266 for instructions on how to return them.
NHF’s Medical and Scientific Advisory Committee (MASAC) has issued Medical Advisory #427 to notify medical providers and community members of the new information in the recall.
In a letter dated Aug. 11, 2020, CSL Behring urged patients to contact their healthcare providers immediately to discuss available treatment options. CSL Behring also noted that patients who received affected lots of Stimate on or after Jan. 10, 2018, “may be eligible for remuneration” after returning the product.
On July 22, NHF and HFA sent a joint letter to Ferring and CSL Behring requesting additional information on several aspects of the recall and are still awaiting a complete response. NHF and HFA will continue keep the bleeding disorders community informed as further information becomes available.
Please note that NHF and HFA do not recommend, endorse or make any representation about the efficacy, appropriateness or suitability of any specific products, treatments, or opinions. If you have any questions or concerns about your medical treatment, including your possible exposure to recalled product, please consult your physician.
Word From Washington